South & Central America Carrier Testing Services Market Size and Forecast (2021 - 2031)

The South & Central America Carrier Testing Services Market is projected to grow significantly, reaching an estimated US$ 100.5 million by 2031, up from US$ 36.1 million in 2024. This growth reflects a robust compound annual growth rate (CAGR) of 16.1% from 2025 to 2031.

Executive Summary and Market Analysis

The carrier testing services market in South & Central America encompasses several key countries, including Brazil, Argentina, Peru, Chile, Colombia, and others in the region. There is a growing awareness of hereditary diseases, particularly in urban areas, which is driving an increase in demand for genetic screening among couples planning to have children.

However, the healthcare systems across South & Central America are not yet equipped to support widespread, routine carrier screening. A significant challenge is the limited number of diagnostic laboratories, which are primarily located in major cities. In response to this, collaborations between international diagnostic companies and local laboratories are becoming more common, facilitating the introduction of advanced testing panels and next-generation sequencing (NGS) technologies. Despite these advancements, the cost of testing remains a barrier to widespread adoption, especially in lower-income regions. Nevertheless, private fertility clinics and specialized diagnostic centers are increasingly recognizing carrier screening as a valuable addition to their prenatal services.

The integration of mobile health technologies and telemedicine is also emerging as a solution to enhance genetic counseling and sample collection services. As governments and private payers begin to understand the public health benefits of early genetic risk detection, there is potential for significant improvements in carrier testing infrastructure. Companies entering this market will face challenges related to navigating diverse regulatory environments and investing in educational initiatives, but the potential rewards are substantial. As adoption rates increase, the market could become a significant contributor to global carrier testing volumes.

Strategic Insights

# Market Segmentation Analysis

The South & Central America Carrier Testing Services Market can be segmented by type, medical conditions, and end users:

• By Type: The market is divided into Expanded Carrier Screening and Targeted Disease Carrier Screening, with the Expanded Carrier Screening segment leading the market in 2024.
• By Medical Conditions: The market is categorized into Pulmonary Conditions, Hematological Conditions, Neurological Conditions, and Other Medical Conditions, where Pulmonary Conditions dominated in 2024.
• By End User: The market is segmented into Hospital-Based Laboratories, Diagnostic Laboratories, and Other End Users, with Hospital-Based Laboratories holding the largest share in 2024.

Market Outlook

The increasing adoption of population-based screening through public health initiatives is transforming carrier screening into a standard preventive health measure. Public health agencies are increasingly exploring genetic screening for clinical or high-risk groups and at the population level, particularly for rare but serious inherited conditions. Experts in public health have identified DNA-based screening for rare pathogenic variants as a promising approach to enhance community health.

Some countries, such as Israel, have already implemented national carrier screening programs funded by the state, covering a wide range of severe genetic diseases and making testing widely accessible. Evidence from these programs indicates that early identification of carriers, followed by appropriate counseling, empowers couples to make informed reproductive choices. As these publicly funded initiatives expand, there is growing interest in offering preconception carrier screening to the general population. Advances in technology now allow for simultaneous testing for serious early-onset diseases, even among healthy individuals without known family histories. Such large-scale screening could significantly reduce the incidence of genetic disorders, particularly in populations with higher carrier frequencies, thereby improving long-term health outcomes and alleviating pressure on healthcare systems.

Laboratories and carrier testing companies that align with these public health initiatives can scale their operations rapidly by forming partnerships with government agencies, hospitals, and community programs. By providing standardized, population-level carrier screening, these companies can generate high volumes of tests while contributing to public health objectives. Over time, these initiatives could normalize carrier testing as part of routine reproductive healthcare, driving demand and integrating carrier screening into the preventive health framework.

Country Insights

The market is further segmented by country, with Brazil, Argentina, and the Rest of South & Central America being the primary focus. Brazil held the largest market share in 2024.

The Brazilian Rare Diseases Network offers a comprehensive public health structure for rare disease diagnostics; however, only a few reference centers currently provide molecular testing. Most advanced tests, such as multi-gene panels, are available only through private providers. Companies like Igenomix Brazil have introduced extensive carrier tests utilizing NGS to detect over 600 genetic disorders. Despite these advancements, Brazil faces a shortage of genetic counselors and qualified professionals, which hampers clinical interpretation and counseling services. The country’s newborn screening program is expanding, but availability varies significantly across regions, with some areas lagging in providing advanced screening for genetic conditions.

Public health institutions in Brazil are adopting sequencing technologies, such as whole-exome sequencing, for complex cases, indicating an improvement in genomic diagnostics capabilities. The Ministry of Health has prioritized congenital anomalies and hemoglobin disorders in its national surveillance efforts. While Brazil presents a market with substantial potential, it also poses considerable complexities. Success in this market requires strong partnerships with public health institutions and private laboratories, a commitment to genetic counseling, and efforts to ensure equitable access across different regions.

Company Profiles

Key players in the South & Central America Carrier Testing Services Market include F. Hoffmann-La Roche Ltd, Quest Diagnostics Inc, Eurofins Scientific SE, Myriad Genetics Inc, Laboratory Corp of America Holdings, MedGenome Inc, Gene By Gene Ltd, Thermo Fisher Scientific Inc., Fulgent Genetics, Inc, and Illumina, Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products to consumers.